Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

NCT01528709 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

173

Enrollment

OTHER

Sponsor class

Conditions

Saphenous Vein Graft Disease

Interventions

DRUG: Atorvastatin 80 mg daily
DRUG: Atorvastatin 10 mg daily

Sponsor

Boca Raton Regional Hospital

Collaborators

[object Object]